CAR-T cell therapy for severe lupus-related low platelets
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with lupus (SLE) and have had low platelets (under 50,000) on at least two blood tests, confirmed by a bone marrow exam.
- Your low platelets did not improve after at least 3 months of high-dose steroids and another immune-suppressing drug (like biologics).
- You can stop most immune-suppressing medications (except hydroxychloroquine) and take only a low dose of steroids during the study.
- You have adequate organ function (liver, kidneys, lungs, heart) and a lymphocyte count above 400 cells/mcL.
- You have not had CAR-T cell therapy before, and do not have severe active lupus affecting the brain, active infections, recent cancer, or other major health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
This trial tests a new type of immunotherapy called CAR-T cell therapy for people with severe lupus that hasn't improved with usual treatments. The therapy uses your own immune cells to target and reduce the abnormal immune response that causes lupus symptoms.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
Hear when a new Autoimmune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.